Hims & Hers Health, Inc.

NYSE:HIMS Lagerbericht

Marktkapitalisierung: US$5.1b

Hims & Hers Health Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Hims & Hers Health wird ein jährliches Gewinn- und Umsatzwachstum von 17.2% bzw. 22.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.8% betragen.

Wichtige Informationen

17.2%

Wachstumsrate der Gewinne

14.8%

EPS-Wachstumsrate

Healthcare Gewinnwachstum20.8%
Wachstumsrate der Einnahmen22.4%
Zukünftige Eigenkapitalrendite24.8%
Analystenabdeckung

Good

Zuletzt aktualisiert07 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow

Nov 05

HIMS: GLP-1 Is Just The Beginning

Oct 17

Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward

Oct 03

Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Oct 01
Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now

Sep 24

Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)

Aug 27

Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade

Aug 20

Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Aug 11
Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage

Aug 07

Hims & Hers: The Thesis Goes Far Beyond GLP-1

Jul 18

Hims & Hers: Buy The Dip To Catch The Next Rip

Jun 24

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Jun 19
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Hims & Hers: The Undervalued Gem Poised For Growth

Jun 18

Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable

Jun 10

Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead

May 21

Hims & Hers Health: An Unforced Error

May 06

Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

May 04
Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry

Apr 24

Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation

Apr 05

Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock

Mar 21

Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health

Mar 12

Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Feb 28
Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Hims & Hers: Turning The Profitability Corner And Returning 28%

Feb 25

Hims & Hers Health: No Clear Moat Besides First Mover Advantage

Jan 23

Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple

Jan 10

Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Jan 07
Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health Q3: The Cheapest Growth Stock Around

Dec 14

Hims & Hers Health: What Would The Author Of 100 Baggers Say?

Nov 30

Hims & Hers: The Most Undervalued Small Cap Stock I See

Nov 08

Hims & Hers: A Promising Company With Resolvable Challenges

Nov 02

Hims & Hers: Specialization Is The Secret To Great Growth

Oct 25

Hims & Hers Health: Can't Get Much Better

Sep 25

The Market Is Wrong On Hims & Hers Health

Sep 18

Hims & Hers: The Current Weakness Creates A Buying Opportunity

Aug 15

Gewinn- und Umsatzwachstumsprognosen

NYSE:HIMS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20262,37616532138410
12/31/20252,00012324930212
12/31/20241,46512519924910
9/30/20241,242101150187N/A
6/30/20241,0671890127N/A
3/31/2024959-25290N/A
12/31/2023872-244773N/A
9/30/2023793-362745N/A
6/30/2023711-471226N/A
3/31/2023616-59-62N/A
12/31/2022527-66-34-27N/A
9/30/2022444-86-29-23N/A
6/30/2022374-83-51-45N/A
3/31/2022321-73-43-38N/A
12/31/2021272-108-39-34N/A
9/30/2021229-82-36-32N/A
6/30/2021196-72-17-12N/A
3/31/2021171-63-18-13N/A
12/31/2020149-18-7-2N/A
9/30/2020132-25-16-13N/A
6/30/2020112-38-43-41N/A
3/31/202095-58-62-60N/A
12/31/201983-72-77-75N/A
12/31/201827-75-57-57N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HIMSDas prognostizierte Gewinnwachstum (17.2% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: HIMSDie Erträge des Unternehmens (17.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: HIMSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: HIMSDie Einnahmen des Unternehmens (22.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: HIMSDie Einnahmen des Unternehmens (22.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: HIMSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.8%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y